CD274 and neoplasm: In IMpassion130 41% of patients were immune cell PD-L1-positive and 8.7% tumor cell PD-L1-positive [40], while the positivity rates (PD-L1 combined positive score ≥ 1) were 75% and 65% in the KEYNOTE-355 and the KEYNOTE-119 studies, respectively [41, 42].